公司新闻 - 亚科因（Abbkine）—服务于细胞和蛋白研究全球用户

首页
技术中心
产品文献

或

货号	产品名称	文献标题	IF	杂志名称
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Acinetobacter baumannii outer membrane protein A induces HeLa cell autophagy via MAPK/JNK signaling pathway	4	Int J Med Microbiol
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Fargesin ameliorates osteoarthritis via macrophage reprogramming by downregulating MAPK and NF-κB pathways	4	Arthritis Res Ther
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Proteomic analysis identifies PFKP lactylation in SW480 colon cancer cells	6	Iscience
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Enhancer of zeste homolog 2 facilitates phenotypic transition of vascular smooth muscle cells leading to aortic aneurysm/dissection	3	Experimental and Therapeutic Medicine
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-κB signaling pathway	3	International Immunopharmacology
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Ets-1 deficiency alleviates nonalcoholic steatohepatitis via weakening TGF-β1 signaling-mediated hepatocyte apoptosis	6	Cell Death Dis
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Enhancer of zeste homolog 2 facilitates phenotypic transition of vascular smooth muscle cells leading to aortic aneurysm/dissection	6	Experimental and Therapeutic Medicine
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	FTO promotes innate immunity by controlling NOD1 expression via m6A-YTHDF2 manner in teleost	6	Iscience
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Newly synthesized AIFM1 determines the hypersensitivity of T lymphocytes to STING activation-induced cell apoptosis	9	Cell Reports
A25022	IPKine小鼠抗兔IgG轻链二抗，HRP标记 (规避重链干扰)	Immune evasion strategy involving propionylation by the KSHV interferon regulatory factor 1 (vIRF1)	7	PLoS Pathogens

首页上一页 266 267 268 269 270 271 下一页尾页

赋能细胞研究与治疗 Enabling cell research and therapy

联系我们

全国服务热线： 400-6800-830

订购邮箱： service@abbkine.com

联系地址：武汉光谷生物医药加速器17号楼1号房2-3层

友情链接：

Copyright ©Abbkine Scientific Co., Ltd- 鄂ICP备10204150号-5

意见反馈

 在线咨询

扫码关注

微信公众号

返回顶部